Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
As long-acting injectables near approval, daily pill versions of the same drugs show long-term benefit.
Cabotegravir plus rilpivirine maintenance therapy worked equally well when taken monthly or every two months.
Recently, ViiV Healthcare applied for approval of the first long-acting injectable HIV regimen.
A roundup of POZ’s reporting on studies presented at the Mexico City conference about HIV treatment, vaccines, PrEP and other concerns.
The experimental long-acting injectable regimen of cabotegravir and rilpivirine stands poised for approval.
Given every four weeks, the combo injection of cabotegravir and Edurant (rilpivirine) will likely face an FDA decision by early 2020.
The trial will investigate whether injections of long-acting cabotegravir and rilpivirine yield a superior rate of viral suppression.
Dosed every four weeks, the injection, which requires a clinic visit, includes long-acting rilpivirine and cabotegravir.
Juluca is a single-tablet regimen for HIV.
A recent study tested the long-acting injectable antiretrovirals cabotegravir and Edurant (rilpivirine) given every four or eight weeks.
Cabotegravir and rilpivirine combo shows promise as well-tolerated and effective antiretroviral regimen in a trial.
Two large trials switched participants from three- or four-drug combos to a regimen of Tivicay (dolutegravir) and Edurant (rilpivirine).
Long-term Viread (tenofovir disoproxil fumarate, or TDF) use is linked with a raised risk of end-stage liver cancer in HIV-positive people.
ViiV Healthcare and Janssen have formalized their collaboration agreement to develop a long-acting, two-drug injectable HIV treatment.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.